Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro.

Trial Profile

Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
    • 14 Jan 2016 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov.
    • 14 May 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top